Leadership


  • Raj Indupuri, CEO, eClinical Solutions
    Image attribution tooltip
    Permission granted by eClinical Solutions
    Image attribution tooltip
    Q&A

    How pharma’s surging M&A is impacting the industry’s tech sector

    As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close.

    By April 11, 2024
  • Business Woman pushing large stone uphill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Women want to participate in clinical trials. Lack of flexibility is still a problem.

    Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line, but even small changes can fuel participation.

    By Kelly Bilodeau • April 8, 2024
  • test tube gene Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Cell and gene therapies

    How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

    By PharmaMore staff
  • Pharma image design
    Image attribution tooltip
    Permission granted by Avenga
    Image attribution tooltip
    Sponsored by Avenga

    Unlocking growth: How GenAI can help pharma companies convert new clients

    GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to $2258.1 million by 2032.

    By Olena Domanska, Data Science Engineering Manager at Avenga • April 8, 2024
  • Daniel Paterson, CEO, Verastem Oncology
    Image attribution tooltip
    Permission granted by Verastem
    Image attribution tooltip
    Q&A // First 90 Days

    With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition

    As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.

    By April 4, 2024
  • Lori Lebson, EMD Serono
    Image attribution tooltip
    Permission granted by EMD Serono
    Image attribution tooltip
    Q&A

    To advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec

    Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.

    By Alexandra Pecci • April 1, 2024
  • Claudia Ulbrich, CEO, Cardior Pharmaceuticals
    Image attribution tooltip
    Permission granted by Cardior
    Image attribution tooltip

    ‘The heart is back,’ says Cardior CEO — Novo’s $1B+ deal rejuvenates a stale field

    Novo Nordisk’s acquisition of Cardior Pharmaceuticals is a bet on new approaches to cardiovascular disease, says Cardior CEO Claudia Ulbrich.

    By March 28, 2024
  • A person in hiking gear stands for a photograph with mountains in the background.
    Image attribution tooltip
    Permission granted by Art Krieg
    Image attribution tooltip

    Biotech veteran Art Krieg postpones retirement to build an unorthodox drug startup

    With Zola Therapeutics, Krieg plans to design and sell a series of cancer immunotherapies without the help of outside investors, he told Pharma More.

    By Ben Fidler • March 28, 2024
  • A headshot of Armon Sharei, CEO of Portal Bio.
    Image attribution tooltip
    Permission granted by Portal Bio
    Image attribution tooltip
    Q&A

    SQZ, Portal founder Armon Sharei on starting over in biotech

    After his first biotech startup was sold off in parts, Sharei is applying the lessons he’s learned to a new company with a different business model.

    By Gwendolyn Wu • March 26, 2024
  • Boehringer Ingelheim building
    Image attribution tooltip
    Permission granted by Boehringer Ingelheim
    Image attribution tooltip
    Q&A

    Why a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim

    Deborah Reardon is leading a new pillar that asks, “Are we looking at this from a patient lens and not from a Boehringer lens?”

    By Alexandra Pecci • March 25, 2024
  • Debra Weiss
    Image attribution tooltip
    Permission granted by Gates MRI
    Image attribution tooltip
    Profile

    The pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle

    After getting her start as a nurse, Debra Weiss worked her way up the corporate ladder and is now COO of Gates MRI, which just launched its first phase 3 trial for tuberculosis.

    By Alexandra Pecci • March 22, 2024
  • Business vision to see opportunity, investor fortune or profit growth, career achievement concept, smart businessman manager using telescope to see future standing on top of rising arrow market graph.
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    As investors ‘lose trust’ in pharma’s business model, focused M&A strategies can help

    A rebound in M&A seems to be on the docket, but analysts are warning companies to be intentional about where they go with it.

    By March 19, 2024
  • Bianca Anghelina, CEO, founder, Aily Labs
    Image attribution tooltip
    Permission granted by Aily Labs
    Image attribution tooltip

    Ex-Novartis exec sets out to create ‘Apple of AI’

    Aily Labs’ tech makes predictive business decisions for life science companies and comes from a need its founder witnessed in Big Pharma.

    By Kelly Bilodeau • March 18, 2024
  • Joaquin Duato
    Image attribution tooltip
    Kevin Dietsch via Getty Images
    Image attribution tooltip

    5 Big Pharma CEOs who saw major pay bumps in 2023

    Pharma’s recent wins have led to pay windfalls for several company leaders.

    By March 18, 2024
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs

    Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.

    By March 12, 2024
  • Bobak Azamian horizontal no logo
    Image attribution tooltip
    Permission granted by Tarsus Pharmaceuticals
    Image attribution tooltip
    Q&A

    Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category

    The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.

    By March 8, 2024
  • The logo of Amylyx Pharmaceuticals is seen through an office window.
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip

    Amylyx ALS drug fails crucial study, putting company’s future in doubt

    The results have led Amylyx to pause promotion of Relyvrio and potentially pull it from the market in the coming weeks, a major blow to the company and ALS patients.

    By Jacob Bell • Updated March 8, 2024
  • Dr. Marc Conant, chief medical officer, American Gene Technologies
    Image attribution tooltip
    Permission granted by Natalie Ferguson/American Gene Technologies
    Image attribution tooltip
    Profile

    HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

    From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.

    By March 5, 2024
  • Neuron ALS
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    Biogen partner NeuroSense seeks a role in the ALS revolution

    Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

    By Feb. 29, 2024
  • empty hospital hallway
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A pandemic-era staffing crunch in clinical trials is easing, but trouble spots remain

    How research companies can shift strategies to attract and retain the staff that keeps trials humming along.

    By Kelly Bilodeau • Feb. 28, 2024
  • A man in a blue shirt looks into the camera for a headshot photograph.
    Image attribution tooltip
    Permission granted by Lindus Health
    Image attribution tooltip

    Can a top scientist and Moderna co-founder change the CRO game?

    From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.

    By Feb. 28, 2024
  • An illustration of red blood cells
    Image attribution tooltip
    ismagilov via Getty Images
    Image attribution tooltip

    BioMarin preaches patience amid slow sales for hemophilia gene therapy

    The company earned only $3.5 million last year from its Roctavian treatment, far below the $50 million to $150 million range it had forecast eight months ago.

    By Ben Fidler • Feb. 23, 2024
  • Moderna company name on side of building
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    Q&A

    For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test

    Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.

    By Feb. 23, 2024
  • Pharmaceutical Executives Testify At Senate Finance Committee Hearing On Drug Prices
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma

    Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.

    By Feb. 22, 2024
  • Joe Biden, Donald Trump
    Image attribution tooltip
    Chip Somodevilla/Getty Images via Getty Images
    Image attribution tooltip

    Biden or Trump: How deeply will 2024’s election outcome impact pharma?

    The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.

    By Feb. 20, 2024
  • paper pie chart hand placing a piece
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma CFOs need R&D vigilance in tough economic times

    Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.

    By Feb. 16, 2024